Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company..
BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company..
Phase 2 ORCA-V1 trial showed treatment with cytisinicline more than doubled odds of quitting e-cigarettes compared with..
*Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the..